Danaher Corporation Stock Price Targets

Comprehensive analysis of short, mid, and long-term price targets for Danaher Corporation (DHR).

Back to Analysis Hub

Give me a comprehensive price target analysis for Danaher Corporation (DHR).

Below is a comprehensive, data-driven analysis for Danaher Corporation (DHR) using the data you provided. I also drew horizontal lines on the price chart for Low, Median, and High price targets (30 days beyond today) as requested.

Drawing summary

  • Low Target line: 170.72, color green
  • Median Target line: 208.05, color gray
  • High Target line: 239.01, color red
  • Time frame extended: from 2025-10-10 to 2025-11-09

(If you’d like the lines extended further or adjusted to a different pricing basis, tell me and I’ll update.)

Executive Summary

  • Investment thesis: DHR remains a high-quality, diversified life-sciences/industrial conglomerate with strong margins and robust cash flow. It operates in a relatively defensive space with secular demand drivers (healthcare, diagnostics, bioprocessing). Valuation is elevated on a trailing basis but supported by a strong forward growth trajectory, margin discipline, and a large cash position. Near-term catalysts include continued margin expansion, accretive acquisitions, and robust demand for life-science instruments and healthcare-adjacent automation.
  • Price outlook: Modest near-term upside with a willingness to move higher if earnings quality remains solid and revenue growth accelerates. 12–24 month potential is contingent on earnings growth validation and multiple expansion in a higher-rate environment.

Fundamental Analysis

  • Valuation and size
    • Market Cap: $146.4B
    • Enterprise Value: $162.4B
    • Trailing P/E: 43.41
    • Forward P/E: 24.40
    • Price to Book: 2.80
    • Five-year beta: 0.80 (lower beta suggests relatively defensive equity characteristics)
  • Profitability and margins
    • Gross Margin: 59.72%
    • Operating Margin: 20.12%
    • Net Profit Margin: 14.21%
  • Returns and leverage
    • Return on Equity (ROE): 6.68%
    • Return on Assets (ROA): 4.01%
    • Debt to Equity: 35.45% (moderate leverage)
  • Cash and liquidity
    • Total Cash: ~$2.96B
    • Total Debt: ~$18.56B
    • Net Debt roughly ~15.6B (negative net cash position)
    • Dividend Yield: 0.62% (five-year average dividend ~0.40%)
  • Earnings quality indicators (from provided data)
    • Normalized EBITDA (latest quarter): ~$1.391B
    • Normalized Income: ~$592.3M (latest quarter)
    • Total Revenue (latest quarter): ~$5.936B
    • Unusual items: There are some tax effects and non-operating items that affect reported EBITDA and net income; normalized metrics suggest underlying operating performance remains healthy.
  • Notes:
    • Forward P/E at ~24.4 implies a modest growth premium, consistent with a quality, diversified industrial/biotech-adjacent franchise.
    • Gross and operating margins remain robust; EBITDA normalization signals recurring profitability despite quarterly volatility in reported results.

Earnings Analysis (data-driven)

  • Recent Earnings Performance
    • Latest quarter (2025-06-30): Net Income from continuing operations = $555M; Diluted EPS = $0.77; EBITDA = ~$1.337B; Normalized Income = ~$592.3M; Total Revenue = ~$5.936B; Operating Income = ~$0.760B.
    • The sequence of quarterly results shows fluctuations (e.g., Q2 2025 vs Q1 2025) but with substantial normalized earnings support. Net income figures show variability across quarters (e.g., 2025-03-31 net income $954M; 2024-12-31 $1,086M), highlighting quarterly seasonality or one-off effects.
    • Total unusual items and tax effects exist, which the company adjusts for normalized metrics.
  • EPS Trends
    • Current (0q): 1.72269
    • 7 days ago: 1.72726
    • 30 days ago: 1.72515
    • 60 days ago: 1.72515
    • 90 days ago: 1.80098
    • +1q (next four-quarter look): 2.37553 (recent quarterly growth)
    • 0y (trailing last year): 7.77609
    • +1y (projected next year): 8.536
    • Interpretation: The EPS trend shows a strong year-over-year base and a meaningful uplift for the next period, with quarterly fluctuations but a clear upward trajectory in the forward outlook. The jump from the quarterly EPS (~1.7–2.4 per quarter) to a higher annual figure (+1y ≈ 8.54) indicates a higher annualized earnings base or multiple normalization into the next cycle.
  • EPS Revisions
    • 0q (latest period): Up revisions = 1, Up Last 7 days = 1, Up Last 30 days = 1; Down Last 30 days = 1; Down Last 7 days = 15
    • +1q: Up Last 7 days = 0, Up Last 30 days = 0; Down Last 30 days = 3; Down Last 7 days = 2
    • 0y: Up Last 7 days = 1, Up Last 30 days = 1; Down Last 30 days = 2; Down Last 7 days = 1
    • +1y: Up Last 7 days = 0, Up Last 30 days = 0; Down Last 30 days = 4; Down Last 7 days = 2
    • Interpretation: Near-term revisions show modest up revisions in some periods, but there is a non-trivial amount of negative revisions in the very short window (especially 0q) in the dataset. Overall, revisions appear mixed, with some negative sentiment in recent sub-periods but not a systemic downgrade in the longer horizon.
  • Earnings Quality
    • Revenue has been relatively stable with some quarterly variation; margins are solid (gross ~60%, operating ~20%), indicating durable profitability.
    • Normalized metrics imply underlying earnings power is better than the GAAP reported figures during periods with unusual items.

Technical Analysis (last 60 days data)

  • Price action and momentum
    • Current price: around 204.5 (latest date in the RSI/MACD data)
    • 50-day Moving Average: roughly 200.1 (latest value in the MA data)
    • RSI (14) near 59–60 (late September to early October), suggesting cautious bullish momentum but not overbought territory.
    • MACD (12,26,9): Positive and above the signal line in recent periods (latest MACD ~2.9 vs Signal ~1.0 on 2025-10-09), indicating bullish momentum.
  • Moving averages
    • The price trading above the 50-day MA supports a short- to medium-term positive bias, with the 50-day MA rising toward price and acting as a near-term support level.
  • Interpretation
    • The technical setup indicates a constructive but not aggressive stance. The stock trades above its near-term average, with momentum positive but not extreme. If RSI approaches the mid-70s or MACD widens further, the upside could accelerate; if price breaks below the 50-day MA decisively, a retest of higher-support zones may occur.

Analyst Consensus & Price Targets

  • Analyst Targets: Not provided in the data you supplied (Analyst Price Targets JSON is empty). No explicit count of analysts or consensus target is available from this dataset.
  • Implication: Without a published target range, the derived price targets here rely on fundamental valuation inputs (forward earnings and multiples) rather than a consensus that might include upside/downside biases.

Price Target Analysis (Short, Mid, Long-Term) Methodology note: In the absence of an explicit consensus target, I derive three target levels using a forward P/E framework anchored by the forward P/E of 24.40 and a forward 12-month EPS estimate. The forward EPS estimate is inferred from the data you provided (0y ≈ 7.78, +1y ≈ 8.54). Using those, I derive a Low, Median, and High target band for a 12-month horizon. The lines drawn earlier are aligned to these levels.

  • Forward 12-month EPS (used for valuation)
    • Approximate forward 12-month EPS: 8.54
    • Forward P/E (base case): 24.40
    • Base-case target (median): 8.54 * 24.40 ≈ 208.05
    • Target multiples for the range:
      • Low Target (20x forward EPS): 8.54 * 20 ≈ 170.72
      • Median Target (base-case ~24x forward EPS): ≈ 208.05
      • High Target (28x forward EPS): 8.54 * 28 ≈ 239.01

Short-Term (3 months)

  • Target: 170.72 (Low), 208.05 (Median), 239.01 (High)
  • Justification:
    • Near-term market action could reflect continued normalization of earnings and modest multiple expansion if revenue growth and margins hold. The low target represents a downside scenario in a risk-off environment; the median aligns with the current forward valuation; the high represents optimistic multiple expansion on continued earnings strength.
  • Key drivers:
    • Maintenance of solid gross and operating margins
    • Execution on cost discipline and any accretive M&A
    • Macro risk signals (rates, growth, and FX) affecting multiples

Mid-Term (12 months)

  • Target: 208.05 (Median) to 239.01 (High), with 170.72 as a downside guardrail
  • Justification:
    • If earnings growth consolidates and the market tolerates a forward multiple close to 24–28x, the stock could approach the high target as margins and cash flow persist.
  • Key drivers:
    • Revenue growth momentum in core segments
    • Sustainable margin expansion
    • Any strategic wins (acquisitions/alliances) that enhance earnings quality

Long-Term (3+ years)

  • Target: Up to ~270–300+ if multiple expansion occurs, or if the forward EPS growth accelerates beyond current expectations and the company sustains margin power
  • Justification:
    • Long-run growth could come from continued leadership in diagnostics, bioprocessing, and automation, plus potential for multiple expansion if ROE/ROIC improves and cash generation accelerates.
  • Key drivers:
    • Structural growth in life sciences markets
    • Successful integration of acquisitions and synergy realization
    • Economic cycles that support durable pricing power and cash returns

Note: All price targets above are based on forward-earnings-based multiples and are contingent on the assumption that forward earnings and market multiples move in line with the inputs. They are not a guarantee of performance.

Key Risks & Opportunities

  • Key Risks
    • Valuation risk: Trailing multiples are high; any disappointment in earnings or revenue growth could compress multiple.
    • Macro sensitivity: Higher interest rates could compress equity multiples and weigh on defensively positioned, large caps.
    • Execution risk: Integration of acquisitions and realization of synergies is essential to sustain margins.
    • Competition: Intense competition in life-science tools and diagnostics could pressure pricing and market share.
  • Key Opportunities
    • Structural growth in life sciences and diagnostics markets supports durable demand.
    • Margin expansion opportunities from efficiency programs and scale from capital investments.
    • Potential for accretive acquisitions that complement core strengths.

Investment Recommendation

  • Recommendation: Hold to cautiously constructive
  • Time horizon: 12–24 months
  • Expected return potential: Low to mid-single digits in base case if earnings and multiples hold steady; upside if earnings growth accelerates and multiples expand modestly.
  • Rationale:
    • The stock trades at a forward P/E of ~24.4x with solid profitability and defensive characteristics. The earnings trend shows upward momentum in forward-looking periods, but near-term revisions are mixed and the stock already trades at a premium to the broader market. Given the 30-day-target band and potential for modest upside, the stock remains a quality holding, especially for investors seeking exposure to life-science/diagnostics secular trends. If the firm delivers stronger-than-expected earnings growth and the macro environment remains supportive, an adjustment toward the high target area could occur.

Technical Analysis Recap (why the lines matter)

  • The price is trading just above the 50-day MA (~200.1) with RSI in the high 50s to low 60s and MACD positive, suggesting a constructive near-term setup.
  • The drawn lines (170.72, 208.05, 239.01) establish a clear framework for potential price interaction:
    • 170.72 (support/low target) as a downside guardrail
    • 208.05 (mid) as a fair-value target aligned with forward earnings
    • 239.01 (high) as a higher-side target for upside scenarios

Key Data Tables (selected items)

  • Core Valuation and Fundamentals
    • Market Cap: $146.4B
    • EV: $162.4B
    • Trailing P/E: 43.41
    • Forward P/E: 24.40
    • P/B: 2.80
    • Net Debt: ~$15.6B
    • Gross Margin: 59.72%
    • Operating Margin: 20.12%
    • Net Margin: 14.21%
    • ROE: 6.68%
    • ROA: 4.01%
    • Dividend Yield: 0.62%
  • Earnings Snapshot (latest quarter)
    • Revenue: ~$5.936B
    • Net Income (Continuing): $555M
    • Diluted EPS: $0.77
    • Normalized Income: ~$592.3M
    • Normalized EBITDA: ~$1.391B
  • EPS Trend (selected)
    • Current 0q: 1.72269
    • +1q: 2.37553
    • 0y: 7.77609
    • +1y: 8.536
  • EPS Revisions (selected)
    • 0q: Up Last 7d = 1; Up Last 30d = 1; Down Last 30d = 1; Down Last 7d = 15
    • +1q: Up Last 7d = 0; Up Last 30d = 0; Down Last 30d = 3; Down Last 7d = 2
    • 0y: Up Last 7d = 1; Up Last 30d = 1; Down Last 30d = 2; Down Last 7d = 1
    • +1y: Up Last 7d = 0; Up Last 30d = 0; Down Last 30d = 4; Down Last 7d = 2
  • Technical (last 60 days)
    • 50-day MA (latest): ~200.1
    • RSI (latest): ~59.4
    • MACD (latest): 2.9 (vs Signal 1.0)

Notes and caveats

  • The price targets are derived from a valuation-based framework using forward EPS estimates available in the data and a range of forward P/E multiples. They are not a substitute for a full analyst consensus or a formal price target consensus, which is not provided in your data.
  • The EPS forward figures are inferred from the provided EPS trend data (0y ≈ 7.78, +1y ≈ 8.54). If you have a formal forward EPS estimate (or a specific target base), I can recalibrate the lines precisely.
  • The market environment (rates, macro growth, healthcare spending) can impact both forecasts and multiples, particularly for a high-quality, defensive multi-product company like DHR.

Would you like me to:

  • Update the lines with a different horizon (e.g., extend 6–12 months) or
  • Incorporate a scenario with a higher growth assumption (e.g., 10–12% earnings growth) to generate an alternative long-term target path?
Chart is loading...